

however, applicant has now corrected all the errors in sequence listing and believes the requirements of 37 CFR 1.821 through 1.825 have now been fully met.


Pursuant to 37 C.F.R. 1.821(c) and (e), a substitute Sequence Listing on compact disc, together with two copies of the substitute Sequence Listing in computer readable form (CRF) (both on compact disc) are being submitted with this Preliminary Amendment. The content of the substitute Sequence Listing and the CRF copies are the same and include no new matter.

No fees are believed to be due for the filing of this Preliminary Amendment. However, the Assistant Commissioner for Patents is hereby authorized to charge any fees owed to Deposit Account No. 50-1728, including fees for an extension of time which, if necessary, is hereby requested.

Respectfully submitted.
EPIGENESIS PHARMACEUTICALS, INC.

3/21/01


Date



Viviana Amzel, Ph.D.
Registration No. 30,930
Attorney for the Applicant

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Legal Dept Phone
413-254-9245 Legal Dept Fax
vamzel@epigene.com E-mail

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, under 37 CFR 1.10 and addressed to Box Sequence, Assistant Commissioner for Patents, on March 21, 2001 by Dee Dee Sutherland.


SIGNATURE